SEC Company Response from Solid Biosciences Inc. (SLDB) (CIK 0001707502) (SLDB) — Jan 22, 2018
Solid Biosciences Inc. (SLDB) (CIK 0001707502)
Date: Jan. 22, 2018 · CIK: 0001707502 · Accession: 0001193125-18-015769
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-222357
Letter
SOLID BIOSCIENCES, LLC
161 First Street, Third Floor
Cambridge, Massachusetts 02142
January 22,
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549-1004
Re: Solid Biosciences, LLC
Registration Statement on Form S-1 (File No. 333-222357)
Acceleration Request:
Requested Date: January 24, 2018
Requested Time: 3:00 PM Eastern Time
Ladies and Gentlemen:
Pursuant to Rule 461 of Regulation C promulgated under the Securities Act of 1933, as amended, Solid Biosciences, LLC (the “Company”) hereby respectfully requests acceleration of the effective date of the above-referenced Registration Statement on Form S-1 (File No. 333-222357) (the “Registration Statement”) so that it may become effective at the “Requested Date” and “Requested Time” set forth above, or as soon thereafter as practicable.
In connection with this acceleration request, the Company hereby acknowledges that:
(a) should the United States Securities and Exchange Commission (the “Commission”) or its staff, acting pursuant to delegated authority, declare the Registration Statement effective, it does not foreclose the Commission from taking any action with respect to the Registration Statement;
(b) the action of the Commission or its staff, acting pursuant to delegated authority, in declaring the Registration Statement effective, does not relieve the Company from its full responsibility for the accuracy and adequacy of the disclosure in the Registration Statement; and
(c) it may not assert staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.
The Company understands that the staff will consider this request as confirmation by the Company of its awareness of its responsibilities under the Securities Act of 1933 and the Securities Exchange Act of 1934 as they relate to the proposed public offering of the securities specified in the Registration Statement.
[Signature page follows]
SOLID BIOSCIENCES, LLC
By:
/s/ Ilan Ganot
Name:
Ilan Ganot
Title:
Chief Executive Officer
[Signature Page – Company Acceleration Request]
Show Raw Text
CORRESP 1 filename1.htm CORRESP SOLID BIOSCIENCES, LLC 161 First Street, Third Floor Cambridge, Massachusetts 02142 January 22, 2018 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549-1004 Re: Solid Biosciences, LLC Registration Statement on Form S-1 (File No. 333-222357) Acceleration Request: Requested Date: January 24, 2018 Requested Time: 3:00 PM Eastern Time Ladies and Gentlemen: Pursuant to Rule 461 of Regulation C promulgated under the Securities Act of 1933, as amended, Solid Biosciences, LLC (the “Company”) hereby respectfully requests acceleration of the effective date of the above-referenced Registration Statement on Form S-1 (File No. 333-222357) (the “Registration Statement”) so that it may become effective at the “Requested Date” and “Requested Time” set forth above, or as soon thereafter as practicable. In connection with this acceleration request, the Company hereby acknowledges that: (a) should the United States Securities and Exchange Commission (the “Commission”) or its staff, acting pursuant to delegated authority, declare the Registration Statement effective, it does not foreclose the Commission from taking any action with respect to the Registration Statement; (b) the action of the Commission or its staff, acting pursuant to delegated authority, in declaring the Registration Statement effective, does not relieve the Company from its full responsibility for the accuracy and adequacy of the disclosure in the Registration Statement; and (c) it may not assert staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States. The Company understands that the staff will consider this request as confirmation by the Company of its awareness of its responsibilities under the Securities Act of 1933 and the Securities Exchange Act of 1934 as they relate to the proposed public offering of the securities specified in the Registration Statement. [Signature page follows] SOLID BIOSCIENCES, LLC By: /s/ Ilan Ganot Name: Ilan Ganot Title: Chief Executive Officer [Signature Page – Company Acceleration Request]